Samuel Isaly’s Orbimed Advisors Llc Opened Huge Puma Biotechnology, Inc Position

February 14, 2018 - By Hazel Jackson

 Samuel Isaly's Orbimed Advisors Llc Opened Huge Puma Biotechnology, Inc Position

Investors sentiment increased to 1.55 in Q3 2017. Its up 0.34, from 1.21 in 2017Q2. It is positive, as 19 investors sold Puma Biotechnology, Inc. shares while 41 reduced holdings. 41 funds opened positions while 52 raised stakes. 35.70 million shares or 3.15% more from 34.61 million shares in 2017Q2 were reported.

Bankshares Of Montreal Can owns 94,246 shares for 0.01% of their portfolio. 498,154 are held by Goldman Sachs Group. Principal Grp Inc reported 0% in Puma Biotechnology, Inc. (NASDAQ:PBYI). Global X Mngmt Ltd Liability Company has invested 0% in Puma Biotechnology, Inc. (NASDAQ:PBYI). Huntington Financial Bank has invested 0% in Puma Biotechnology, Inc. (NASDAQ:PBYI). Envestnet Asset Mgmt reported 94 shares or 0% of all its holdings. Sei Investments stated it has 0% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI). Balyasny Asset Mngmt Limited Company reported 187,759 shares. Sg Americas Lc holds 0% in Puma Biotechnology, Inc. (NASDAQ:PBYI) or 2,634 shares. Fisher Asset Mngmt Limited Liability holds 0% or 15,545 shares. Fred Alger Mgmt Inc invested in 0.1% or 187,118 shares. Citigroup Inc reported 29,565 shares stake. Illinois-based First Advisors Lp has invested 0% in Puma Biotechnology, Inc. (NASDAQ:PBYI). Perceptive Lc owns 923,820 shares. Northwestern Mutual Wealth Co reported 50 shares.

Since September 6, 2017, it had 0 buys, and 6 selling transactions for $4.70 million activity. $1.80M worth of Puma Biotechnology, Inc. (NASDAQ:PBYI) shares were sold by BRYCE RICHARD PAUL. 1,858 shares were sold by Lo Steven, worth $172,515 on Monday, January 22. 669 shares valued at $62,117 were sold by EYLER CHARLES R on Monday, January 22.

The New Samuel Isaly’s Orbimed Advisors Llc Holding in Puma Biotechnology, Inc

Orbimed Advisors Llc reported SC 13G/A form with the SEC for Puma Biotechnology, Inc. Access it here: 000117266118000534. As reported by Samuel Isaly’s Orbimed Advisors Llc, the filler owns 3.30% or 1,238,846 shares of the Health Care–company.

Puma Biotechnology, Inc stake is new for [reportingPerson]. Date of activity: December 31, 2017. This shows Samuel Isaly’s Orbimed Advisors Llc’s positive view for Puma Biotechnology, Inc. For a hedge fund managing $6.70 billion in assets and having 72+ experts this is interesting position.

The hedge fund is investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Samuel Isaly’s Orbimed Advisors Llc’s portfolio is in the sector.

Puma Biotechnology, Inc Institutional Sentiment

Filings show 152 investors own Puma Biotechnology, Inc. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 2411433. 27595042 were owned by these investors. 12 funds opened new Puma Biotechnology, Inc stakes, 61 increased positions. There were 46 that closed positions and 55 reduced them.

Cornerstone Capital Management Llc is an investor bullish on Puma Biotechnology, Inc, owning 495145 shares as of Q3 2015 for 1.58% of its portfolio. Avalon Global Asset Management Llc owns 32900 shares or 1.79% of its portfolio. MA Adage Capital Partners Gp Llc have 1.19% of its portfolio for 5686668 shares. Further, Bb Biotech Ag reported stake worth 1.25% of its portfolio. The NC Franklin Street Advisors Inc owns 14395 shares. Puma Biotechnology, Inc is 0.22% of its portfolio.

Business Profile

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

SEC Form 13G.

Samuel Isaly’s Orbimed Advisors Llc website.

Analysts await Puma Biotechnology, Inc. (NASDAQ:PBYI) to report earnings on March, 7. They expect $-2.04 earnings per share, 0.00 % or $0.00 from last year’s $-2.04 per share. After $-2.07 actual earnings per share reported by Puma Biotechnology, Inc. for the previous quarter, Wall Street now forecasts -1.45 % EPS growth.

The stock decreased 0.96% or $0.6 during the last trading session, reaching $61.65. About 478,110 shares traded. Puma Biotechnology, Inc. (NASDAQ:PBYI) has risen 23.65% since February 14, 2017 and is uptrending. It has outperformed by 6.95% the S&P500.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. The company has market cap of $2.31 billion. The Company’s drug candidates include PB272 ) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). It currently has negative earnings. The firm also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.

More important recent Puma Biotechnology, Inc. (NASDAQ:PBYI) news were published by: Fool.com which released: “Here’s Why Puma Biotechnology Inc. Is Getting Beaten Down Today” on January 24, 2018, also Businesswire.com published article titled: “Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference”, Seekingalpha.com published: “Puma Biotechnology: EU Delivers A Blow – And An Opportunity” on January 25, 2018. More interesting news about Puma Biotechnology, Inc. (NASDAQ:PBYI) was released by: Nasdaq.com and their article: “Commit To Buy Puma Biotechnology At $35, Earn 12.3% Using Options” with publication date: February 06, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: